MedTrace Logo

Drug Resistant Epilepsy: Clinical and Genetic Study

NCT04166305 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2019-11-18

No results posted yet for this study

Summary

This study is to identify the clinical criteria of drug resistant epilepsy and to explore whether SCN1A c.3184 A/G (rs2298771) and ccl2(rs1024611) polymorphisms could serve as genetic based biomarkers to predict drug resistance among epileptic patient.

Conditions

  • Epilepsy, Drug Resistant

Interventions

GENETIC

Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:

DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN). Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism

Sponsors & Collaborators

  • Mansoura University Hospital

    lead OTHER

Principal Investigators

  • Esmael M Ahmed, MD · Assistant Prof of Neurology

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2020-10-01
Completion
2020-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04166305 on ClinicalTrials.gov